Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo.

Shen X, Li Q, Wang F, Bao J, Dai M, Zheng H, Lao X

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie20 Sept 2018Cited by 8 (Europe PMC)

PMID30243095DOI10.1016/j.biopha.2018.09.064PepBankPUB-30243095

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with 4T1 breast tumors, the Tα1-Fc fusion protein inhibited tumor growth more than Tα1.
In plain wordsIn mice with breast tumors, a long-acting thymosin alpha1 fusion protein slowed tumor growth more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
Decrease4T1 breast cancer growth
Study
mousen: not reported in source
4T1 tumor model
Comparator
Thymosin alpha1
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The results showed that Tα1-Fc was more potent than Tα1 in inhibiting the growth of 4T1 and MCF-7 breast cancer cells in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309501
02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In an in vivo MCF-7 breast cancer model, the Tα1-Fc fusion protein inhibited tumor growth more than Tα1.
In plain wordsIn a breast cancer model, a long-acting thymosin alpha1 fusion protein slowed tumor growth more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
DecreaseMCF-7 breast cancer growth
Study
n: not reported in source
MCF-7 breast cancer in vivo
Comparator
Thymosin alpha1
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The results showed that Tα1-Fc was more potent than Tα1 in inhibiting the growth of 4T1 and MCF-7 breast cancer cells in vivo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309502
03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice with 4T1 tumors, Tα1-Fc treatment gave higher CD4 cell levels than Tα1 treatment.
In plain wordsIn mice with breast tumors, the fusion protein raised CD4 immune cells more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD4 cell level in 4T1 tumor model
Study
mousen: not reported in source
4T1 tumor model
Comparator
Thymosin alpha1
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Furthermore, in the 4T1 tumor model the mice treated with Tα1-Fc exhibited higher level of CD4 and CD8 cells compared with that of the mice Tα1 treated.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309503
04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice with 4T1 tumors, Tα1-Fc treatment gave higher CD8 cell levels than Tα1 treatment.
In plain wordsIn mice with breast tumors, the fusion protein raised CD8 immune cells more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD8 cell level in 4T1 tumor model
Study
mousen: not reported in source
4T1 tumor model
Comparator
Thymosin alpha1
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Furthermore, in the 4T1 tumor model the mice treated with Tα1-Fc exhibited higher level of CD4 and CD8 cells compared with that of the mice Tα1 treated.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309504
05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice, interferon-γ was higher with Tα1-Fc than with Tα1.
In plain wordsIn mice, the fusion protein raised interferon-gamma more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseInterferon-γ level
Study
mousen: not reported in source
4T1 tumor model
Comparator
Thymosin alpha1
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The interferon-γ and interleukin-2 level in the Tα1-Fc-treated mice was higher than that in the Tα1-treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309505
06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice, interleukin-2 was higher with Tα1-Fc than with Tα1.
In plain wordsIn mice, the fusion protein raised interleukin-2 more than thymosin alpha1.
Peptide
Thymosin alpha-1
Outcome
IncreaseInterleukin-2 level
Study
mousen: not reported in source
4T1 tumor model
Comparator
Thymosin alpha1
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The interferon-γ and interleukin-2 level in the Tα1-Fc-treated mice was higher than that in the Tα1-treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309506
07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice, Tα1-Fc alleviated immunosuppression induced by hydrocortisone.
In plain wordsIn mice, the fusion protein eased immune suppression caused by hydrocortisone.
Peptide
Thymosin alpha-1
Outcome
DecreaseHydrocortisone-induced immunosuppression
Study
mousen: not reported in source
Hydrocortisone-induced immunosuppression
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Tα1-Fc could also alleviate immunosuppression induced by hydrocortisone.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we fused Tα1 to Fc domain of human IgG1 for generation of a novel long-acting fusion protein, termed Tα1-Fc.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-3024309507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.